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Abstract: A series of hybrids comprising of 5-cyanopyrimidine and quinoline moiety were 
synthesized and tested for in vitro antiplasmodial activity against NF54 and Dd2 strains of 
Plasmodium falciparum. Hybrid bearing m-nitrophenyl substituent at C-4 of pyrimidine 
displayed the highest antiplasmodial activity [IC50 = 56 nM] against the CQR (Dd2) strain, which 
is four–fold greater than CQ.  
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1. Introduction 
Malaria is one of the major causes of morbidity and mortality around the globe and is 
caused by protozoa of the genus Plasmodium of which P. falciparum is the most lethal and 
widespread species. A recent report of the WHO1 indicated over 190 million cases of malaria and 
approximately 5,84,000?? deaths in 2013. The emerging resistance to the existing antiplasmodial 
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drugs,2 absence of new antiplasmodial drugs3 and the slow pace of the development of clinically 
approved vaccines4 further compromise the efficient control of this disease. With no licensed 
malaria vaccines currently in hand, several vaccine projects are in clinical trials, and of these, the 
most advanced vaccine (RTS, S/AS01) has been evaluated in a Phase 3 clinical trial and is active 
only against Plasmodium falciparum. The situation is further exacerbated by the decreased 
clinical efficacy of front-line artemisinin combination therapies (ACTs) currently used for the 
treatment of malaria.5 These factors exemplify the need to discover new, effective, and 
affordable antiplasmodial chemotherapeutic agents acting through novel mechanisms.  
Substituted quinolines are historically6 among the most important antiplasmodial agents 
and their vast use in the 20th century provided well founded hopes for the eradication of malaria. 
The most important drugs of this family include chloroquine (CQ, 1), quinine, mefloquine, 
amodiaquine, piperaquine and primaquine (Figure 1). CQ and related 4-aminoquinolines are 
believed to inhibit the formation of crystalline hemozoin from free ferriprotoporphyrin IX, which 
is generated during proteolysis of host hemoglobin in the acidic food vacuole (FV) and is toxic to 
the parasite.6,7 However, the extensive use of CQ for the treatment of P. falciparum malaria led 
to the development of resistance, which is linked to the mutations in the FV membrane protein 
Pfcrt (P. falciparum chloroquine resistance transporter), which might result in reduced 
accumulation of CQ in chloroquine-resistant strains.8,9  
Insert here Figure 1. 
To overcome CQ-resistance by P. falciparum, a hybridization approach has proven to be 
a promising tool as the hybrid drugs act through different mechanisms against either a single or 
multiple targets and lead to acceptable pharmacological and safety profiles.10 In the design of 
hybrid drugs, the 4-aminoquinoline nucleus has received increasing attention owing to their low 
cost and good activity-toxicity profiles. Pyrimidines being one of the essential cell constituents 
represent one of the most important heterocycles that exhibit remarkable pharmacological 
activities.11 Pyrimidines bearing a nitrile war head were reported to display excellent inhibitory 
activity against  both falcipain-2 as well as cultured P. falciparum.12 The nitrile groups are 
known to exert antiplasmodial effect by forming a reversible thioimidate intermediate with 
cysteine residues of cysteine proteases, which ultimately results in the inhibition of the 
enzyme.13-15 
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     In our previous reports on pyrimidine-quinoline hybrids16, we demonstrated high (nM) 
antiplasmodial activity of this class of hybrids against both chloroquine-sensitive (CQS) and 
chloroquine-resistant (CQR) strains of P. falciparum, which in some cases was even greater than 
CQ.  As an extension of our research interest in this class of hybrids, we herein report on the 
synthesis and antiplasmodial activity of novel pyrimidine-quinoline hybrids bearing a cyano 
group at the C-5 position of the pyrimidine, which is covalently linked to the quinoline ring 
through different linkers. Further, we also report on the efficacy of these hybrids to bind heme as 
well as µ-oxo heme in order to understand the possible mode of action of these hybrids. 
 
Chemistry 
Pyrimidine-quinoline hybrids reported in this work were prepared using the synthetic 
protocol outlined in Scheme 1. The substituted pyrimidin-6(1H)-ones 10 were prepared by using 
a modified Biginelli condensation reaction of ethyl cyanoacetate 7, appropriately substituted 
benzaldehyde 8 and S-methylisothiourea hemisulphate salt 9a/N-morpholinyl guanidine 
hydrochloride 9b, in ethanol in the presence of K2CO3.17 Further, treatment of appropriate 10 
with excess POCl3 afforded the corresponding 6-chloropyrimidine derivatives 11, in quantitative 
yields. The nucleophilic displacement reaction of 11 with 7-chloro-4-aminoquinoline18 12 in dry 
THF yielded corresponding hybrids 13 in 82-92% (Table 1) after column chromatographic 
purification. The structures of all the hybrids were established on the basis of spectral (1H NMR, 
13C NMR, EIMS, FTIR) as well as microanalytical data (vide experimental). The structure of 
13d was additionally confirmed by single crystal x-ray analysis (Table S1). The ortep diagram of 
13d is shown in Figure 2. 
Insert here Figure 2. 
Insert here Scheme 1. 
Insert here Table 1. 
 
3 Results and discussion 
3.1 In vitro antiplasmodial activity and structure-activity relationships (SARs) 
The hybrids 13a-l were evaluated for their activity against CQS (NF 54) and CQR (Dd2) 
strains of P. falciparum using CQ and artesunate (ASN) reference drugs. The concentrations 
inhibiting 50% of parasite growth (IC50) were obtained using a non-linear dose-response curve 
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fitting analysis via Graph Pad Prism v. 4.0 software (Table 1). Analysis of the antiplasmodial 
activity data revealed that most of the hybrids (except 13d and 13g) showed significant (nM) 
activity against CQS [43.8-197.9 nM (NF54)] as well as CQR strains [55.8-1529.7 nM (Dd2)] of 
P. falciparum. Among all the hybrids assayed, hybrid 13e depicted the highest antiplasmodial 
activity [IC50 = 55.8 nM (Dd2)] against the CQR strain, which is four–fold greater than CQ [IC50 
= 257.6 nM (Dd2)]. Comparison of antiplasmodial activity of the homologues 13a [IC50 = 133.7 
nM (NF54); 319.4 nM (Dd2)] and 13b [IC50 = 108.6 nM (NF54); 295.2 nM (Dd2)] showed that 
a four-methylene spacer confers superior antiplasmodial activity compared to a three-methylene 
spacer. Further, the replacement of the flexible aliphatic linker of 13a-c with a piperazinyl linker 
in 13d, led to a complete loss of activity. It is possibly due to the steric restrictions conferred by 
the piperazinyl linker (Figure 2b) in 13d, which may restrict face-to-face stacking of the 
quinoline unit with heme,19 leading to inefficient inhibition of the heme polymerization to 
hemozoin. This fact is experimentally supported by titration of monomeric heme with 13d. 
Gradual addition of 0-37.3 µM of 13d (Figure S1-S2) to a solution of monomeric heme (2.4 µM, 
DMSO:H2O/ 4:6, v/v)  revealed no change in the absorbance at 402 nm indicating lack of a 
binding interaction. 
Similarly, replacement of the diaminopropyl linker with a less basic aminopropoxy linker in 
13c caused a marginal increase in the antiplasmodial activity against both the tested P. 
falciparum strains. This is in contrast to our earlier finding,16c where a similar change of the 
linker led to significant loss in antiplasmodial activity. However, in addition to the nature of the 
linker, the antiplasmodial activity of the current series of pyrimidine-quinoline hybrids seems to 
be benefitted by the presence of a cyano group on the pyrimidine unit, which are known to 
inhibit cysteine proteases13-15 and show antiplasmodial effects.  
Comparison of the antiplasmodial activity of the hybrids 13b, 13e, 13f, 13h and 13k 
suggested that 13e [IC50 = 68.5 nM (NF54, CQS); 55.8 nM (Dd2, CQR)] bearing a m-nitro 
substituent at the C-4 phenyl ring showed highest activity against both the P. falciparum strains. 
Moreover, position of the nitro substituent on the aromatic ring also significantly modulated 
(Table 1) the antiplasmodial activity. Thus, the m-NO2 substituted analogue [13e: IC50 = 68.5 nM 
(NF54); 55.8 nM (Dd2)] showed superior activity against CQR strain, while, a p-NO2 [13f: IC50 
= 43.8 nM (NF54); 531.6 nM (Dd2)] substituted derivate was more active against CQS strain. In 
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the case of methoxy substituted hybrids (13h-j), all the hybrids depicted good antiplasmodial 
activity against the CQS strain and mild activity against CQR strain, except the 3,4,5-
trimethoxyphenyl substituted hybrid 13j [IC50 = 90.9 nM (NF54); 89.9 nM (Dd2)], which 
exhibited 3-fold greater antiplasmodial activity than CQ [IC50 = 257.6 nM (Dd2)] against CQR 
strain and is  the second most potent [IC50 = 90.9 nM (NF54); 89.9 nM (Dd2)]  hybrid of the 
current series of compounds. Furthermore, replacement of the C-2 S-methyl group of the 
pyrimidine unit in 13b [IC50 = 197.9 nM (NF54); 385.8 nM (Dd2)] by morpholine ring to yield 
hybrid 13l [IC50 = 108.6 nM (NF54); 295.2 nM (Dd2)] led to a deterioration of antiplasmodial 
activity against both CQS as well as CQR strains. The molecular weight of these hybrids is close 
to 500 and CLogP values are in the range 5-7.51 (Table 1). While the selectivity indices (SI) of 
these hybrids are low, the most active hybrids 13e (RI = 0.81) and 13j (RI = 0.98) depicted good 
resistance index, which is better than the standard antiplasmodial drugs (CQ & ASN, Table 1).  
This brief SAR study on the new pyrimidine-quinoline hybrids clearly demonstrated that the 
antiplasmodial activity of these hybrids was significantly influenced by the cyano group at C-5 
position, type and length of the methylene spacer linking pyrimidine and quinoline units as well 
as the substitution pattern (C-2 as well as C-4 positions) of the pyrimidine unit.  
3.2 Cytotoxicity  
Cytotoxicity of 13a-l and reference CQ was evaluated using murine leukemia cells (L1210), 
human T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa). The cytotoxicity 
data revealed that most of these hybrids except 13d and 13g were more cytotoxic than CQ 
against all the three tested mammalian tumor cell lines (Table 2). Moreover, the SI of all the 
hybrids [1.9-103.7 (CQS); 1.1- 44.0(CQR)] is lower than CQ [SI = 972.9 (CQS); 69.8 (CQR)]. 
However, the SI of the most active hybrids 13e and 13j, against CQR strain was higher (Table 2) 
and approached that of CQ. Thus, these hybrids display cytotoxicity (Table 2) only at 
concentrations that are significantly higher than concentrations at which hybrids displayed 
antiplasmodial activity. 
Insert here Table 2. 
3.3 Antiviral activity  
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Antiplasmodial drugs such as CQ, artemisinin, and quinine inhibit several RNA and DNA 
viruses.20 CQ being a weak lysosomotropic base exerts antiviral activity by inhibiting replication 
of some viruses either through reducing the efficiency of endosome-mediated virus entry or 
through inhibiting the low-pH-dependent proteases in trans-Golgi vesicles.21-22 Taking into 
consideration the antiviral activity of CQ, we evaluated antiviral activity of hybrids 13a-l against 
several viruses such as (i) herpes simplex virus-1 (KOS), herpes simplex virus-2 (G), vaccinia 
virus, vesicular stomatitis virus, herpes simplex virus-1 (TK-KOS ACVr) and adenovirus using 
HEL cell cultures (ii) vesicular stomatitis virus, coxsackie virus B4, respiratory syncytial virus in 
HeLa cell cultures, (iii) parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, 
Punta Toro virus in Vero cell cultures, (iv) cytomegalovirus using AD-169 and Davis strain in 
HEL cell cultures, (v) varicella-zoster virus (VZV) in HEL cell cultures (Table S2-S3) and (vi) 
influenza A virus (H1N1 and H3N2)  and influenza B virus in MDCK cell cultures, (Table S2-
S3). The data showed that none of the hybrids display any antiviral activity at subtoxic 
concentrations (Table S2-S3).  
3.4 Possible mode of antiplasmodial effects 
Malarial parasite invades the host red blood cells and feed on the hemoglobin. The released 
heme byproduct Fe(III)-protoporphyrin IX, is toxic to the parasite, and is sequestered into 
physiologically insoluble hemozoin crystals (heme detoxification).6 Quinoline drugs form π-π 
complex with heme ferriprotoporphyrin IX (FPPIX) in FV, and inhibit the formation of 
hemozoin crystals.6-7 This inhibition of heme crystallization leads to the accumulation of heme in 
FV thereby causing parasite death. Thus, quinoline drugs exert antimalarial effect by inhibiting 
the heme detoxification process. In order to get an insight into the possible mode of action of 
these hybrids we decided to evaluate the binding of the most potent hybrid 13e (Table 1) of the 
current series with monomeric as well as dimeric heme using UV-visible absorption 
spectrophotometery.16 
The titrations were performed at pH 7.4 as well as 5.6 representing the acidic pH of the food 
vacuole. The sequential addition of 13e [pH 7.4: 0−18.3 μM; pH 5.6: 0−52.5 μM (DMSO)] to a 
solution of monomeric heme in 0.02 M HEPES buffer in aqueous DMSO representing a constant 
concentration (2.4 μM) showed a substantial decrease in the absorption intensity of the Soret 
band of Fe(III)PPIX at 402 nm without significant shift in the position of the absorption band 
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(Figure 3A-4A). This significant hypochromism indicated complexation between Fe(III)PPIX 
and quinolone unit of 13e. Further, the Job’s plot revealed 1:1 stoichiometry of the most stable 
complex of 13e with monomeric heme at pH 7.5 and 5.6 (Figure 3B-4B).  
Insert here Figure 3. 
To ascertain the formation of the proposed complex, mass spectrum of the complex 
obtained by mixing equimolar solutions of hemin chloride (0.24 mM) and 13e (0.24 mM) was 
recorded. The spectrum depicted an intense molecular ion peak at m/z 1135.4094 (Figure 5), 
corresponding to the molecular formula C59H54ClFeN11O6S of the 1:1 complex.  
Further, it is known that CQ binds to heme dimer (µ-oxo heme)23 and thus the binding 
assay was extended to µ-oxo heme also. Titration of µ-oxo heme (10 µM, 0.02 M phosphate 
buffer) with sequential addition of 13e (0-13.7 µM) at pH 5.8 showed a decrease in the intensity 
of the broad peak at 364 nm (Figure 6A). Further, the Job’s plot calculations indicated a 1:1 
stoichiometry for the most stable complex of µ-oxo heme and 13e (Figure 6B). A similar 
titration of CQ with heme was also performed under identical conditions, and the association 
constants were compared (Table 3). 
Insert here Figure 4. 
Insert here Figure 5. 
The association constants (Table 3) were calculated from the titration data obtained for 
monomeric heme (at pH 7.4 and 5.6) and µ-oxo heme using HypSpec, a nonlinear least-squares 
fitting program.24 The greater association constants of 13e with both monomeric (pH 7.4 and pH 
5.6) as well as µ-oxo heme compared to CQ (Table 3) suggested stronger complexation of 13e 
with heme. Furthermore, the observed trend of the binding of the hybrid with heme (Table 3) 
suggested stronger binding at the lower pH. The comparison of association constants of 13e for 
monomeric and µ-oxo heme revealed that the hybrid has greater affinity for the µ-oxo heme and 
thus, possibly inhibits hemozoin formation by blocking the growing face of heme leading to the 
observed antiplasmodial activity. The calculated association constants of 13e are quite 
comparable with the hybrids16 lacking a C-5 carbonitrile, this suggested that the primary 
mechanism of action of these hybrids is through inhibition of heme polymerization, although the 
cysteine protease inhibition might be playing a supportive role.  
Insert here Figure 6.  
9 
 
Insert here Table 3. 
4. Conclusions 
Covalently linked hybrids of pyrimidine-5-carbonitrile and 4-aminoquinoline display 
structure-dependent antiplasmodial activity in nM range, which is superior to the corresponding 
hybrids lacking the 5-cyano group on the pyrimidine unit. The hybrids possessing a nitrophenyl 
group at the C-4 position and a SMe group at the C-2 position of the pyrimidine unit are more 
effective against both CQ-sensitive and CQ-resistant strains. The hybrids 13e and 13j displayed 
the highest antiplasmodial activity against the Dd2 (CQR) strain. However, the current design of 
hybrids gave a lower selectivity index compared to CQ. From the heme binding studies, it is 
concluded that inhibition of hemozoin formation is the primary mechanism of antiplasmodial 
activity of this class of hybrids, while the cyano substitution seems to play a positive but a 
supportive role.   
5 Experimental  
5.1 General information 
All liquid reagents were dried/purified following recommended drying agents and/or 
distilled over 4 Å molecular sieves. THF was dried (Na- benzophenone ketyl) under nitrogen. 1H 
NMR (300 MHz, 400 MHz and 500 MHz), 13C (75 MHz, 100 MHz and 125 MHz), were 
recorded in CDCl3 and DMSO-d6 on a multinuclear Jeol FT-AL-300 spectrometer and 
BrukerAvance II 400 & III 500 spectrometer with chemical shifts being reported in parts per 
million (δ) relative to internal tetramethylsilane (TMS, δ 0.0, 1H NMR) or chloroform (CDCl3, δ 
77.0, 13C NMR). Mass spectra were recorded on a Bruker LC-MS MICROTOF II spectrometer. 
Elemental analysis was performed on FLASH EA 112 (Thermo electron Corporation) analyzer 
and the results are quoted in %. IR spectra were recorded on Perkin Elmer FTIR-C92035 Fourier 
transform spectrometer in the range 400-4000 cm-1 using KBr pellets. For monitoring the 
progress of a reaction and for comparison purpose, thin layer chromatography (TLC) was 
performed on pre-coated aluminum sheets of Merck (60F254, 0.2 mm) using an appropriate 
solvent system. The chromatograms were visualized under UV light. For column 
chromatography silica gel (60-120 mesh) was employed and eluents were ethyl acetate/hexane or 
ethyl acetate/methanol mixtures. The pH measurements were performed with the Equip-Tronics 
Digital pH meter model-EQ 610. The purities of all the final compounds were confirmed to be ≥ 
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95% by combustion methods. UV-visible spectral studies were conducted on Shimadzu 1601 PC 
spectrophotometer with a quartz cuvette (path length, 1 cm). The absorption spectra have been 
recorded between 1100 and 200 nm. The cell holder of the spectrophotometer was thermostatted 
at 25ºC for consistency in the recordings.  
5.2 Synthesis of pyrimidin-6(1H)-ones (10a-h) 
5.2.1  Synthesis of 5-cyano-2-methylthio-4-phenylpyrimidin-6(1H)-one (10a) 
In a typical procedure, to a solution of S-methylisothiourea (1 g, 11.10 mmol), 
benzaldehyde (2.23 ml, 22.10 mmol), and ethyl cyanoacetate (2.37 ml, 22.10 mmol) in ethanol 
(40 ml), K2CO3 (3.06 g, 22.10 mmol) was added. The reaction mixture was heated to 80 ºC for 5 
h and filtered after cooling to isolate the corresponding product. Recrystallization from methanol 
provided 10a as yellow crystalline solids in 84% yield. Rf: 0.75 (ethyl acetate). m.p. > 250 ºC 
(methanol). IR (KBr): νmax 1469, 1563, 1656, 2195, 3061, 3234 cm-1. 1H NMR (500 MHz, 
DMSO-d6, 25 ºC): δ 2.35 (s, 3H, SCH3), 7.45-7.47 (m, 3H, ArH), 7.75 (t, 2H, J 5.8 Hz, ArH). 
13C NMR (125 MHz, DMSO-d6, 25 ºC): δ 13.7, 89.0, 120.7, 126.6, 127.4, 128.5, 129.2, 130.0, 
138.1, 167.3, 170.9 and 172.9. Anal. Calcd. for C12H9N3OS: C, 59.26; H, 3.70; N, 17.28, S, 
13.18. Found: C, 59.31; H, 3.80; N, 17.19, S, 13.30. EIMS: m/z 244 (M+H) +. UV/vis (DMSO): 
λmax (ε/L mol-1 cm-1) 328 nm (57900). 
Following the above procedure and using appropriate aldehyde, 10b-g were analogously 
prepared. For the preparation of 10h, condensation of benzaldehyde, ethyl cyanoacetate and N-
morpholinyl guanidine hydrochloride was performed. The experimental details as well as 
characteristic data of 10b-h are presented in the supplementary data. 
5.3 Synthesis of 4-aryl-5-cyano-6-chloro-2-methylthiopyrimidines (11a-h) 
5.3.1 Synthesis of 5-cyano-6-chloro-2-(methylthio)-4-phenylpyrimidine (11a) 
A suspension of 10a (0.50 g, 2.05 mmol) in distilled POCl3 (5 ml, 53.80 mmol) was 
heated at 105 οC for 3 h and the excess POCl3 was removed under reduced pressure. The residue 
was purified by column chromatography (60-120 mesh silica) using ethyl acetate/hexane as 
chromatograpic eluent (1:9 v/v) to obtain the product as white solid in 97% yield. Rf: 0.74 [ethyl 
acetate:hexane/1:4 (v/v)]. m.p. 110 ºC (dichloromethane/hexane). IR (KBr): νmax 1474, 1537, 
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2228, 3066 cm-1. 1H NMR (500 MHz, CDCl3, 25 ºC): δ 2.66 (s, 3H, SCH3), 7.52-7.54 (m, 3H, 
ArH), 8.03 (d, 2H, J 10.0 Hz, ArH). 13C NMR (125 MHz, CDCl3, 25 ºC):  δ 14.7, 100.7, 114.6, 
128.5, 128.9, 129.2, 130.1, 132.5, 134.3, 163.5, 168.5, and 176.4. Anal. Calcd. for C12H8ClN3S: 
C, 55.17; H, 3.06; N, 16.09, S, 12.25. Found: C, 55.22; H, 3.11; N, 16.17; S, 12.34. EIMS: m/z 
261 (M+). UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 286 nm (9160). 
Following the similar procedures and using appropriate 10b-h, 11b-h were analogously 
prepared. The experimental details as well as characteristic data of 10b-h are presented in the 
supplementary data. 
5.4  General procedure for the synthesis of pyrimidine-5-carbonitrile-quinoline hybrids 
 The solution of appropriate 4-aminoquinoline 12 (3.38 mmol) in dry THF (10 ml) was 
added to the stirred solution of 11 (1.69 mmol) and potassium carbonate (8.45 mmol) in dry THF 
(20 ml). The reaction mixture was stirred at room temperature for 48 h and upon completion 
(TLC), the reaction mixture was filtered and the filtrate was concentrated under vacuum. The 
residue was purified by column chromatography over 60-120 mesh silica using hexane/ethyl 
acetate or ethyl acetate/methanol (13a-l) as eluent. Using this procedure, the following 
compounds were isolated.  
2-Methylthio-4-phenyl-6-[(7-chloroquinolin-4-yl)aminopropyl]aminopyrimidine-5- 
carbonitrile (13a) 
Chromatograpic eluent: ethyl acetate/methanol (99:1 v/v). White solid. Rf: 0.40 (ethyl acetate). 
Yield: 87%. m.p. 205-207ºC (dichloromethane/hexane). IR (KBr): νmax 1583, 2209, 2935, 3343 
cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 2.06 (t, 2H, J 6.0 Hz, CH2), 2.58 (s, 3H, SCH3), 3.46 
(t, 2H, J 6.0 Hz, CH2), 3.74-3.81 (m, 2H, CH2), 5.55 (br, 1H, D2O exchangeable, NH), 5.87 (br, 
1H, D2O exchangeable, NH), 6.44 (d, 1H, J 5.4 Hz, ArH), 7.38 (dd, 1H, J 2.4 Hz, 6.6 Hz, ArH), 
7.48-7.52 (m, 3H, ArH), 7.87 (d, 1H, J 9.0 Hz, ArH), 7.95-7.98 (m, 3H, ArH), 8.53 (d, 1H, J 5.1 
Hz, ArH). 13C NMR (75 MHz, CDCl3, 25 οC): δ 14.0, 27.5, 42.0, 42.2, 83.5, 99.1, 116.8, 117.9, 
124.4, 127.8, 128.9, 131.4, 133.8, 136.4, 149.4, 150.4, 152.2, 161.6, 167.3 and 174.4. Anal. 
Calcd. for C24H21ClN6S: C, 62.60; H, 4.56; N, 18.26, S, 6.95. Found: C, 62.41; H, 4.64; N, 
18.13; S, 6.88. EIMS: m/z 461 (M+H) +. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 254 nm (39198), 
324 nm (15040). 
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2-Methylthio-4-phenyl-6-[(7-chloroquinolin-4-yl)aminobutyl]aminopyrimidine-5-
carbonitrile (13b) 
Chromatograpic eluent: ethyl acetate/methanol (99:1 v/v). White solid. Rf: 0.50 (ethyl acetate). 
Yield: 82%. m.p. 160-162 ºC (dichloromethane/hexane). IR (KBr): νmax 1578, 2213, 2927, 3060, 
3282 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 1.87-1.92 (m, 4H, 2×CH2), 2.56 (s, 3H, SCH3), 
3.42-3.45 (m, 2H, CH2), 3.60-3.69 (m, 2H, CH2), 5.03 (br, 1H, D2O exchangeable, NH), 5.74 (br, 
1H, D2O exchangeable, NH), 6.44 (d, 1H, J 5.1 Hz, ArH), 7.36 (d, 1H, J 2.1 Hz, ArH), 7.39-7.53 
(m, 3H, ArH), 7.68 (d, 1H, J 9.0 Hz, ArH), 7.95-7.97 (m, 3H, ArH), 8.55 (d, 1H, J 5.4 Hz, ArH). 
13C NMR (75 MHz, CDCl3, 25 οC): δ 14.0, 25.5, 26.5, 41.0, 42.5, 79.6, 83.3, 99.1, 116.7, 117.9, 
124.4, 124.5, 127.9, 128.9, 131.4, 133.8, 136.4, 149.5, 150.5, 152.3, 161.5, 167.3 and 174.4. 
Anal. Calcd. for C25H23ClN6S: C, 63.29; H, 4.85; N, 17.72;  S, 6.75. Found: C, 63.14; H, 4.72; 
N, 17.64; S, 6.67. EIMS: m/z 475 (M+H) +. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 nm 
(23710), 324 nm (7210). 
2-Methylthio-4-phenyl-6-[(7-chloroquinolin-4-yl)aminopropoxy]pyrimidine-5-carbonitrile (13c)  
Chromatograpic eluent: ethyl acetate/methanol (99:1 v/v). White solid. Rf: 0.50 (ethyl acetate). 
Yield: 89%. m.p. 138-140 ºC (dichloromethane/hexane). IR (KBr): νmax 1332, 1580, 2220, 3061, 
3212 cm-1.1H NMR (300 MHz, CDCl3, 25 oC): δ 2.29-2.33 (m, 2H, CH2), 2.62 (s, 3H, SCH3), 
3.59-3.62 (m, 2H, CH2), 4.72 (t, 2H, J 5.4 Hz, CH2), 5.40 (br, 1H, D2O exchangeable, NH), 6.49 
(d, 1H, J 5.1 Hz, ArH), 7.39 (dd, 1H, J 2.1 Hz, 9.0 Hz, ArH), 7.42-7.56 (m, 3H, ArH), 7.82 (d, 
1H, J 9.0 Hz, ArH), 7.95 (d, 1H, J 1.8 Hz, ArH), 8.06-8.03 (m, 2H, ArH), 8.55 (d, 1H, J 5.7 Hz, 
ArH). 13C NMR (75 MHz, CDCl3, 25 οC): δ 14.4, 27.7, 40.2, 66.5, 100.1, 115.4, 116.3, 121.3, 
125.6, 128.8, 128.9, 131.9, 135.2, 148.4, 150.3, 152.6, 165.3, 168.5 and 173.2. Anal. Calcd. for 
C24H20ClN5OS: C, 62.47; H, 4.33; N, 15.18; S, 6.94. Found: C, 62.54; H, 4.31; N, 15.11; S, 6.90. 
EIMS: m/z 462 (M+H)+. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 nm (10780), 312 nm (3280). 
2-Methylthio-4-phenyl-6-[1-(7-chloroquinolin-4-yl]piperazin-4-yl]pyrimidine-5-carbonitrile 
(13d)  
Chromatograpic eluent: ethyl acetate/hexane (80:20 v/v).White solid. Rf: 0.87 (ethyl acetate). 
Yield: 85%. m.p. 188-190 ºC (dichloromethane/hexane). IR (KBr): νmax 1578, 2206, 2822, 2924, 
3035 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 2.59 (s, 3H, SCH3), 3.38 (t, 4H, J 4.8 Hz, 
2×CH2), 4.27 (t, 4H, J 4.8 Hz, 2×CH2), 6.88 (d, 1H, J 4.8 Hz, ArH), 7.46-7.57 (m, 4H, ArH), 
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7.89 (dd, 2H, J 1.5 Hz, 6.3 Hz, ArH), 7.98 (d, 1H, J 9.0 Hz, ArH), 8.08 (d, 1H, J 2.1 Hz, ArH), 
8.76 (d, 1H, J 4.8 Hz, ArH). 13C NMR (75 MHz, CDCl3, 25 οC): δ 14.4, 47.2, 51.9, 84.1, 109.3, 
118.3, 124.7, 126.6, 128.5, 129.0, 129.3, 131.4, 135.2, 136.1, 150.1, 151.9, 156.1, 162.9, 170.8 
and 174.5. Anal. Calcd. for C25H21ClN6S: C, 63.55; H, 4.44; N, 17.79; S, 6.77. Found: C, 63.61; 
H, 4.34; N, 17.71; S, 6.70. EIMS: m/z 473 (M+H)+. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 
nm (14890), 329 nm sh (2330). 
2-Methylthio-4-(m-nitrophenyl)-6-[(7-chloroquinolin-4-yl)aminobutyl]aminopyrimidine-5-
carbonitrile (13e) 
Chromatograpic eluent: ethyl acetate/hexane (90:10 v/v).Yellow solid. Rf: 0. 34 (ethyl acetate). 
Yield: 84%. m.p. 155-157 ºC (dichloromethane/hexane). IR (KBr): νmax 1347, 1583, 1725, 2202, 
3056, 3360 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 1.86-1.88 (m, 4H, 2×CH2), 2.69 (s, 3H, 
SCH3), 3.40-3.43 (m, 2H, CH2), 3.70-3.72 (m, 2H, CH2), 5.01 (br, 1H, D2O exchangeable, NH), 
5.82 (br, 1H, D2O exchangeable, NH), 6.44 (d, 1H, J 5.7 Hz, ArH), 7.38 (dd, 1H, J 2.1 Hz, 4.5 
Hz, ArH), 7.69 (dd, 1H, J 7.1 Hz, 13.8 Hz, ArH), 7.96 (d, 1H, J 2.1 Hz, ArH), 8.29 (d, 1H, J 7.1 
Hz, ArH), 8.38 (d, 2H, J 7.2 Hz, ArH), 8.55 (d, 1H, J 5.4 Hz, ArH), 8.82 (s, 1H, ArH). 13C NMR 
(75 MHz, CDCl3, 25 οC): δ 13.6, 24.9, 25.9, 40.5, 42.1, 83.0, 96.9, 98.5, 115.6, 117.3, 123.1, 
123.7, 123.8, 125.1, 127.1, 129.8, 133.6, 134.4, 137.4, 147.6, 150.2, 151.3, 160.8, 164.2 and 
174.3 . Anal. Calcd. for C25H22ClN7O2S: C, 57.80; H, 4.23; N, 18.88, S, 6.16; Found: C, 57.68; 
H, 4.23; N, 18.89; S, 6.27;. EIMS: m/z 520 (M+H) +. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 
nm (15770), 326 nm (3350). 
2-Methylthio-4-(p-nitrophenyl)-6-[(7-chloroquinolin-4-yl)aminobutyl]aminopyrimidine-5-
carbonitrile (13f) 
Chromatograpic eluent: ethyl acetate/hexane (90:10 v/v). Yellow solid. Rf: 0.45 (ethyl acetate). 
Yield: 88%. m.p. 150-152 ºC (dichloromethane/hexane). IR (KBr): νmax 1351, 1547, 1580, 2208, 
2927, 3065, 3335 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 1.86-1.91 (m, 4H, 2×CH2), 2.57 (s, 
3H, SCH3), 3.42-3.44 (m, 2H, CH2), 3.71-3.73 (m, 2H, CH2), 6.43 (d, 1H, J 5.4 Hz, ArH), 7.37 
(dd,  1H, J 2.4 Hz, 9.0 Hz, ArH), 7.68 (d, 1H, J 2.4 Hz, ArH), 7.96 (d, 1H, J 2.1 Hz, ArH), 8.10 
(dd, 2H, J 1.8 Hz, 9.0 Hz, ArH), 8.35 (dd, 2H, J 1.8 Hz, 6.0 Hz, ArH), 8.53 (d, 1H, J 5.4 Hz, 
ArH). 13C NMR (75 MHz, CDCl3, 25 οC): δ 13.6, 24.9, 25.9, 40.5, 42.0, 98.3, 101.5, 117.4, 
123.3, 123.8, 127.1, 129.8, 133.5, 141.8, 148.5, 150.2, 151.3, 160.8 and 174.3. Anal. Calcd. for 
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C25H22ClN7O2S: C, 57.80; H, 4.23; N, 18.88, S, 6.16; Found: C, 57.68; H, 4.23; N, 18.89; S 6.27. 
EIMS: m/z 520 (M+H) +. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 nm (19840), 320 nm 
(4630). 
2-Methylthio-4-(p-nitrophenyl)-6-[1-(7-chloroquinolin-4-yl]piperazin-4-ylpyrimidine-5-
carbonitrile (13g)  
Chromatograpic eluent: ethyl acetate/hexane (80:20 v/v). White solid. Rf: 0.54 (ethyl acetate). 
Yield: 91%. m.p. 190 ºC (dichloromethane/hexane). IR (KBr): νmax 1423, 1533, 2210, 2923, 
3039 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 2.59 (s, 3H, SCH3), 3.50-3.52 (m, 4H, 2×CH2), 
4.30-4.33 (m, 4H, 2×CH2), 6.92 (d, 1H, J 5.4 Hz, ArH), 7.52 (dd, 1H, J 2.0 Hz, 9.0 Hz, ArH), 
7.98-8.07 (m,  3H, ArH), 8.19 (s, 1H, ArH), 8.35 (d, 2H, J 9.0 Hz, ArH), 8.75 (d, 1H, J 5.1 Hz, 
ArH). 13C NMR (75 MHz, CDCl3, 25 οC): δ 13.5, 14.1, 29.5, 29.7, 46.9, 51.6, 123.4, 126.9, 
130.3 and 152.2. Anal. Calcd. for C25H20ClN7O2S: C, 58.02; H, 3.86; N, 18.95; S, 6.19. Found: 
C, 57.91; H, 4.00; N, 18.90; S, 6.19. EIMS: m/z 518 (M+H) +. UV/vis (CH2Cl2): λmax (ε/L mol-1 
cm-1) 252 nm (15690), 323 nm sh (4678). 
 
2-Methylthio-4-(p-methoxylphenyl)-6-[(7-chloroquinolin-4-yl)aminobutyl]aminopyrimidine-5-
carbonitrile (13h) 
Chromatograpic eluent: ethyl acetate/hexane (80:20 v/v). Yellow solid. Rf: 0.46 (ethyl acetate). 
Yield: 80%. m.p. 145-147 ºC (dichloromethane/hexane). IR (KBr): νmax 1050, 1259, 1566, 2210, 
2948, 3309 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 1.77-1.79 (m, 4H, 2×CH2), 2.48 (s, 3H, 
SCH3), 3.30-3.33 (m, 2H, CH2), 3.60-3.62 (m, 2H, CH2), 3.80 (s, 3H, OCH3), 5.00 (br, 1H, D2O 
exchangeable, NH), 5.70 (br, 1H, D2O exchangeable, NH), 6.36 (d, 1H, J 5.4 Hz, ArH), 6.93 (d, 
2H, J 9.0 Hz, ArH), 7.30 (d, 1H, J 7.2 Hz, ArH), 7.60 (d, 1H, J 8.7 Hz, ArH), 7.95-7.89 (m, 3H, 
ArH), 8.47 (d, 1H, J 5.1 Hz, ArH). 13C NMR (75 MHz, CDCl3, 25 οC): δ 16.7, 28.4, 29.4, 32.1, 
45.1, 57.9, 101.5, 116.4, 123.3, 127.9, 131.2, 132.9 and 154.4. Anal. Calcd. for C26H25ClN6OS: 
C, 61.90; H, 4.96; N, 16.66, S, 6.34. Found: C, 61.74; H, 5.03; N, 16.71; S, 6.43. EIMS: m/z 505 
(M+H) +. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 nm (13940), 310 nm (7140). 
2-Methylthio-4-(3,4-dimethoxylphenyl)-6-[(7-chloroquinolin-4-yl)aminobutyl] 
aminopyrimidine-5-carbonitrile (13i) 
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Chromatograpic eluent: ethyl acetate/hexane (85:15 v/v). Yellow solid. Rf: 0.39 (ethyl acetate). 
Yield: 85%. m.p. 108 ºC (dichloromethane/hexane). IR (KBr): νmax 1022, 1262, 1489, 1581, 
2202, 2963, 3351 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 1.72-1.75 (m, 4H, 2×CH2), 2.45 
(s, 3H, SCH3), 3.29-3.31 (m, 2H, CH2), 3.57-3.59 (m, 2H, CH2), 3.84 (d, 6H, J 3.0 Hz, 
2×OCH3), 5.05 (br, 1H, D2O exchangeable, NH), 5.70 (br, 1H, D2O exchangeable, NH), 6.31 (d, 
1H, J 5.4 Hz, ArH), 6.85 (d, 1H, J 8.4 Hz, ArH), 7.26 (t, 1H, J 6.9 Hz, ArH), 7.47 (d, 1H, J 2.1 
Hz, ArH), 7.57-7.60 (m, 2H, ArH), 7.85 (d, 1H, J 2.1 Hz, ArH), 8.41 (d, 1H, J 5.1 Hz, ArH). 13C 
NMR (75 MHz, CDCl3, 25 οC): δ 13.1, 24.9, 26.3, 28.6, 40.4, 44.9, 55.0, 98.2, 110.4, 118.1, 
121.3, 127.3, 147.1, 151.3, 160.3, 162.3 and 176.1. Anal. Calcd. for C27H27ClN6O2S: C, 60.67; 
H, 5.05; N, 15.73, S, 5.99. Found: C, 60.68; H, 5.04; N, 15.62; S, 5.94. EIMS: m/z 535 (M+H) +. 
UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 nm (18390), 322 nm (13280). 
 
2-Methylthio-4-(3,4,5-trimethoxylphenyl)-6-[(7-chloroquinolin-4-yl)aminobutyl] 
aminopyrimidine-5-carbonitrile (13j) 
Chromatograpic eluent: ethyl acetate/hexane (90:10 v/v). Yellow solid. Rf: 0.37 (ethyl acetate). 
Yield: 83%. m.p. 100-102 ºC (dichloromethane/hexane). IR (KBr): νmax 1220, 1487, 1581, 2204, 
2934, 3106, 3341 cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 1.87-1.90 (m, 4H, 2×CH2), 2.50 
(s, 3H, SCH3), 3.40-3.42 (m, 2H, CH2), 3.69-3.71 (m, 2H, CH2), 3.91 (s, 9H, 3×OCH3), 5.88 (br, 
1H, D2O exchangeable, NH), 6.04 (br, 1H, D2O exchangeable, NH), 6.34 (d, 1H, J 5.7 Hz, ArH), 
7.32 (d, 1H, J 2.4 Hz, ArH), 7.35 (d,  1H, J 2.1 Hz, ArH), 7.80 (d, 2H, ArH), 7.92 (d, 1H, J 2.1 
Hz, ArH), 8.40 (d, 1H, J 5.7 Hz, ArH). 13C NMR (75 MHz, CDCl3, 25 οC): δ 14.3, 25.7, 26.9, 
40.9, 42.9, 56.3, 60.9, 82.8, 98.4, 99.9, 106.1, 116.5, 117.1, 122.3, 125.7, 125.9, 130.9, 136.0, 
140.8, 148.9, 151.2, 153.1, 161.9, 166.1, 175.1 and 177.1. Anal. Calcd. for C28H29ClN6O3S: C, 
59.57; H, 5.14; N, 14.89, S, 5.67. Found: C, 59.50; H, 5.09; N, 14.80; S, 5.69. EIMS: m/z 565 
(M+H) +. UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 252 nm (16970), 320 nm (9340). 
 
2-Methylthio-4-(p-methylphenyl)-6-[(7-chloroquinolin-4-yl)aminobutyl]aminopyrimidine-5-
carbonitrile (13k) 
Chromatograpic eluent: ethyl acetate/hexane (90:10 v/v). Yellow solid. Rf: 0.42 (ethyl acetate). 
Yield: 84%. m.p. 153-155 ºC (dichloromethane/hexane). IR (KBr): νmax 1577, 2203, 2926, 3244 
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cm-1. 1H NMR (300 MHz, CDCl3, 25 oC): δ 1.81-1.86 (m, 4H, 2×CH2), 2.43 (d, 3H, J 3.6 Hz, 
CH3), 2.57 (s, 3H, SCH3), 3.42-3.44 (m, 2H, CH2), 3.66-3.70 (m, 2H, CH2), 5.72 (br, 1H, D2O 
exchangeable, NH), 6.43 (d, 1H, J 5.4 Hz, ArH), 7.68 (d, 1H, J 8.7 Hz, ArH), 7.86-7.89 (m, 5H, 
ArH), 7.96 (d, 1H, J 2.1 Hz, ArH), 8.53 (d, 1H, J 5.1 Hz, ArH). 13C NMR (75 MHz, CDCl3, 25 
οC): δ 13.6, 21.0, 24.9, 26.1, 40.2, 42.2, 82.4, 98.3, 116.4, 117.4, 123.8, 127.1, 128.3, 128.7, 
133.1, 133.5, 140.8, 150.2, 151.3, 161.2 and 173.8. Anal. Calcd. for C26H25ClN6S: C, 63.86; H, 
5.15; N, 17.18, S, 6.56; Found: C, 63.79; H, 5.09; N, 17.11; S, 6.49. EIMS: m/z 489 (M+H) +. 
UV/vis (CH2Cl2): λmax (ε/L mol-1 cm-1) 254 nm (36200), 329 nm (12960). 
 
2-(Morpholin-4-yl)-4-phenyl-6-[(7-chloroquinolin-4-yl)aminobutyl]aminopyrimidine-5-
carbonitrile (13l) 
Chromatograpic eluent: ethyl acetate/hexane (90:10 v/v).  White solid. Rf: 0.40 (ethyl acetate). 
Yield: 92%. m.p. 178-180 οC (dichloromethane/hexane). IR (KBr): νmax 1443, 2204, 2965, 3340 
cm-1. 1H NMR (500 MHz, CDCl3, 25 οC): δ 1.80-1.86 (m, 4H, 2×CH2), 3.40-3.42 (m, 2H, CH2), 
3.63-3.65 (m, 2H, CH2), 3.74-3.78 (m, 4H, 2×CH2), 3.88-3.92 (m, 4H, 2×CH2), 5.02 (br, 1H, 
D2O exchangeable, NH), 5.55 (br, 1H, D2O exchangeable, NH), 6.44 (d, 1H, J 5.1 Hz, ArH), 
7.38 (d, 1H, J 7.3 Hz, ArH), 7.49-7.51 (m, 3H, ArH), 7.67 (d, 1H, J 8.9 Hz, ArH), 7.93-7.98 (m, 
3H, ArH), 8.55 (d, 1H, J 5.7 Hz, ArH). 13C NMR (125 MHz, CDCl3, 25 οC): δ 26.2, 27.0, 40.6, 
42.9, 44.2, 66.7, 99.0, 116.9, 118.5, 120.7, 125.5, 128.3, 128.4, 128.5, 128.7, 130.8, 135.0, 137.0, 
148.7, 148.9, 149.6, 151.8, 160.4, 163.5 and 168.5. Anal. Calcd. for C28H28ClN7O: C, 65.49; H, 
5.45; N, 19.10; Found: C, 65.41; H, 5.60; N, 19.01. EIMS: m/z 514 (M+H) +. UV/vis (CH2Cl2): 
λmax (ε/L mol-1 cm-1) 252 nm (13020), 326 nm (3380). 
 
6 Material and Methods for biological activity determination  
6.1 In vitro antimalarial activity assay 
The test samples were tested in triplicate on one or two separate occasions against 
chloroquine sensitive (CQS) NF54 and chloroquine-resistant (CQR) Dd2 strains of P. falciparum. 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method of Trager and Jensen.25 Quantitative assessment of antiplasmodial 
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activity in vitro was determined via the parasite lactate dehydrogenase assay using a modified 
method described by Makler.26 
The test samples were prepared to a 20 mg/ml stock solution in 100% DMSO. Samples were 
tested as a suspension. Stock solutions were stored at -20 ºC. Further dilutions were prepared on 
the day of the experiment. Chloroquine (CQ) and artesunate were used as the reference drugs in 
all experiments. A full dose-response was performed for all compounds to determine the 
concentration inhibiting 50% of parasite growth (IC50–value). Test samples were tested at a 
starting concentration of 100 μg/ml, which was then serially diluted 2-fold in complete medium 
to give 10 concentrations; with the lowest concentration being 0.2 μg/ml. The same dilution 
technique was used for all samples. Reference drugs were tested at a starting concentration of 
1000 ng/ml. Active samples were tested at a starting concentration of 1000 ng/ml. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on the 
parasite viability (data not shown). The IC50-values were obtained using a non-linear dose 
response curve fitting analysis via Graph Pad Prism v.4.0 software. 
6.2 Cytotoxicity and antiviral activity assays 
Cytotoxicity was determined by exposing different concentrations of  the samples to 
murine leukemia cells (L1210) and human T-lymphocyte cells (CEM) and human cervix 
carcinoma cells (HeLa).16 The cytotoxic activity was determined by measuring the 50% 
cytotoxic concentration of compound that inhibited tumor cell proliferation by 50% as measured 
by a Coulter counter. The antiviral assays were based on inhibition of virus-induced 
cytopathicity in HEL [herpes simplex virus type 1 (HSV-1), HSV-2 (G), vaccinia virus, and 
vesicular stomatitis virus], Vero (parainfluenza-3, reovirus-1, Coxsackie B4, and Punta Toro 
virus), HeLa (vesicular stomatitis virus, Coxsackie virus B4, and respiratory syncytial virus) and 
MDCK (influenza A (H1N1; H3N2) and B virus) cell cultures. Confluent cell cultures in 
microtiter 96-well plates were inoculated with 100 cell culture inhibitory dose-50 (CCID50) of 
virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) in the presence of varying 
concentrations of the test compounds. Viral cytopathicity was recorded as soon as it reached 
completion in the control virus-infected cell cultures that were not treated with the test 
compounds. The cytotoxicity was microscopically determined or examined with the viability 
staining (MTT) method. 
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Captions for Figures 
Figure 1. Quinoline based antimalarial drugs. 
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Figure 2. (A) Ortep diagram of 13d showing stereo view of the molecule and the numbering 
scheme used in the structure analysis (CCDC number: 1019022). (B) View showing orientation of 
piperazinyl ring w.r.t quinoline ring. 
 
Figure 3. (A) UV-visible absorption changes in the titration of 13e with monomeric heme at pH 
7.4; (B) Job plot of monomeric heme complex formation at pH 7.4. x = [13e]/[13e]+[heme] is 
the mole fraction of the 13e, A0 is the absorbance, when x = 1 and A is the absorbance at 
respective values of x. 
  
Figure 4. (A) UV-visible absorption changes in the titration of 13e with monomeric heme at pH 
5.6; (B) Job plot of monomeric heme complex formation at pH 5.6. x = [13e]/[13e]+[heme] is 
the mole fraction of the 13e, A0 is the absorbance, when x = 1 and A is the absorbance at 
respective values of x. 
 
Figure 5. (A) The solution phase mass spectrum of 13e (0.24 mmol) upon addition of monomeric 
heme (0.24 mmol) in 40% aqueous DMSO solution (inset shows zoom between m/z 1000 and 
2500). 
 
Figure 6. (A) UV-visible absorption changes in the titration of 13e with µ-oxo heme at pH 5.8; 
(B) Job plot of µ-oxo heme complex formation at pH 5.8 x = [13e]/[13e]+[heme] is the mole 
fraction of the 13e, A0 is the absorbance, when x = 1 and A is the absorbance at respective values 
of x. 
 
Caption for Scheme 
Scheme  1. Synthesis of pyrimidine-5-carbonitrile-quinoline hybrids. 
 
Captions for Tables 
Table 1. In vitro antiplasmodial activity of 13a-l against P. falciparum (CQS) NF54 strain and 
(CQR) Dd2 strain for n = 3 (n = number of replicates). 
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Table 2. In vitro cellular toxicity of 13a-l and CQ against murine leukemia cells (L1210), human 
T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa). 
 
Table 3. Binding constants (log K) of 13e and CQ with heme and µ-oxoheme.  
 
 
